Almas Jabeen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Almas Jabeen has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Shaheen Faizi
H.E.J Research Institute of Chemistry International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
6 shared publicationsSidrah Shams
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
5 shared publicationsFarwa Naqvi
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan
4 shared publicationsSyeda Farah Shah
Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
4 shared publicationsMuhammad Raza Shah
International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi, Pakistan
3 shared publicationsShabana U. Simjee
H.E.J Research Institute of Chemistry International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
3 shared publications
Latest Publications
- 9 October 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1) , 124
Eupatorin interferes with NLRP3 inflammasome activation via modulation of NF-κB signaling pathway in LPS induced macrophages
- 9 October 2026
- Published by Springer Nature in Immunologic Research
- Vol. 74 (1) , 124
Eupatorin interferes with NLRP3 inflammasome activation via modulation of NF-κB signaling pathway in LPS induced macrophages
- 26 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17677-17691
Dihydroxyflavones as potential therapeutic agents against inflammation and renal injury via p38 MAP kinase inhibition: an in silico and experimental study
Nephrotoxicity poses a significant clinical challenge, contributing to renal complications and increased mortality, thus necessitating novel therapeutics with superior efficacy and safety. Our study addresses this need by evaluating flavone derivatives as potential modulators of p38-MAPK to tackle both inflammation and renal damage, using cell-based assays, cytotoxicity profiling, molecular docking, and ADME-T profiling. Notably, 3,6-dihydroxyflavone (3,6-DHF) and 3,7-dihydroxyflavone (3,7-DHF) demonstrated a significant reduction in KIM-1 mRNA expression in CCl4-induced damaged renal epithelial cells while exhibiting no cytotoxic effects on Vero cells at therapeutic doses. Protein slot blot analyses revealed alteration in expression of total p38-MAPK, with 3,6-DHF exhibiting the strongest inhibitory effect. On the other hand, both DHFs effectively quenched reactive oxygen and nitrogen species from phagocytes, underscoring their anti-inflammatory properties. Molecular docking showed high binding affinity for p38-MAPK, with values of - 6.8 kcal/mol for 3,6-DHF and - 6.05 kcal/mol for 3,7-DHF, while ADME-T profiling revealed compliance with the Lipinski rule, good gastrointestinal absorption, and low toxicity risk. The findings suggest the promising anti-inflammatory and renoprotective properties of 3,6-DHF and 3,7-DHF, offering potential benefits for the treatment of nephropathies and associated inflammation. Future directions involve in vivo validation using nephrotoxicity models and preclinical optimization of these compounds for potential clinical application in treating renal disorders.
- 26 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17677-17691
Dihydroxyflavones as potential therapeutic agents against inflammation and renal injury via p38 MAP kinase inhibition: an in silico and experimental study
Nephrotoxicity poses a significant clinical challenge, contributing to renal complications and increased mortality, thus necessitating novel therapeutics with superior efficacy and safety. Our study addresses this need by evaluating flavone derivatives as potential modulators of p38-MAPK to tackle both inflammation and renal damage, using cell-based assays, cytotoxicity profiling, molecular docking, and ADME-T profiling. Notably, 3,6-dihydroxyflavone (3,6-DHF) and 3,7-dihydroxyflavone (3,7-DHF) demonstrated a significant reduction in KIM-1 mRNA expression in CCl4-induced damaged renal epithelial cells while exhibiting no cytotoxic effects on Vero cells at therapeutic doses. Protein slot blot analyses revealed alteration in expression of total p38-MAPK, with 3,6-DHF exhibiting the strongest inhibitory effect. On the other hand, both DHFs effectively quenched reactive oxygen and nitrogen species from phagocytes, underscoring their anti-inflammatory properties. Molecular docking showed high binding affinity for p38-MAPK, with values of - 6.8 kcal/mol for 3,6-DHF and - 6.05 kcal/mol for 3,7-DHF, while ADME-T profiling revealed compliance with the Lipinski rule, good gastrointestinal absorption, and low toxicity risk. The findings suggest the promising anti-inflammatory and renoprotective properties of 3,6-DHF and 3,7-DHF, offering potential benefits for the treatment of nephropathies and associated inflammation. Future directions involve in vivo validation using nephrotoxicity models and preclinical optimization of these compounds for potential clinical application in treating renal disorders.
- 24 March 2026
- Published by Springer Nature in Journal of Cluster Science
- Vol. 37 (2) , 52
Pre-clinical Assessment of Nanoliposome Encapsulated Dodecyl Gallate for the Treatment of Inflammatory Diseases
- 24 March 2026
- Published by Springer Nature in Journal of Cluster Science
- Vol. 37 (2) , 52
Pre-clinical Assessment of Nanoliposome Encapsulated Dodecyl Gallate for the Treatment of Inflammatory Diseases
- 18 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4123
Patuletin Ameliorates Inflammation and Letrozole–Induced Polycystic Ovarian Syndrome in Rats
Concerns about inflammation‐related issues affecting female reproductive health are growing. Chronic low‐grade inflammation in women with polycystic ovarian syndrome (PCOS) affects follicular growth, ovulation, and androgen production. The present investigation aimed to elucidate the efficacy of flavonoid patuletin in ameliorating the letrozole–induced PCOS and associated inflammation in rats. Female Wistar rats (32 days old) were divided into five groups (n = 12): Group I, control; Group II, vehicle control; Group III, letrozole oral (1 mg/kg) for 28 days; Group IV and Group V treatment groups, patuletin i.p. (25 mg/kg) and clomiphene citrate + metformin i.p. (50 mg/kg + 300 mg/kg), respectively. Leterozole–induced PCOS and ovarian inflammation were ameliorated by patuletin, as reflected in the improved histopathology, prevention of cyst formation, significant upregulation of growth factors such as growth differentiation factor 9 (GDF‐9) and bone morphogenetic protein‐15 (BMP‐15) expression, and a decrease in the pro‐inflammatory cytokines TNF‐α, IL‐6, and COX‐2. Additionally, the plasma levels of reproductive hormones were restored. Upregulation of FSH‐R, PR, and CYP19a1, along with downregulation of ERα, LHR, CYP17a1, CYP11a1 and HSDβ17a1, showed the regulation of gonadotropin receptors and steroid biosynthesis genes in ovarian tissues. Patuletin demonstrated a promising protective approach against the biological model of PCOS by increasing the inflammation in ovarian tissues with consequent regulation of growth factors, enzymes, and hormones, and might be used as adjuvant therapy in the treatment of problems related to female reproductive health.
- 18 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4123
Patuletin Ameliorates Inflammation and Letrozole–Induced Polycystic Ovarian Syndrome in Rats
Concerns about inflammation‐related issues affecting female reproductive health are growing. Chronic low‐grade inflammation in women with polycystic ovarian syndrome (PCOS) affects follicular growth, ovulation, and androgen production. The present investigation aimed to elucidate the efficacy of flavonoid patuletin in ameliorating the letrozole–induced PCOS and associated inflammation in rats. Female Wistar rats (32 days old) were divided into five groups (n = 12): Group I, control; Group II, vehicle control; Group III, letrozole oral (1 mg/kg) for 28 days; Group IV and Group V treatment groups, patuletin i.p. (25 mg/kg) and clomiphene citrate + metformin i.p. (50 mg/kg + 300 mg/kg), respectively. Leterozole–induced PCOS and ovarian inflammation were ameliorated by patuletin, as reflected in the improved histopathology, prevention of cyst formation, significant upregulation of growth factors such as growth differentiation factor 9 (GDF‐9) and bone morphogenetic protein‐15 (BMP‐15) expression, and a decrease in the pro‐inflammatory cytokines TNF‐α, IL‐6, and COX‐2. Additionally, the plasma levels of reproductive hormones were restored. Upregulation of FSH‐R, PR, and CYP19a1, along with downregulation of ERα, LHR, CYP17a1, CYP11a1 and HSDβ17a1, showed the regulation of gonadotropin receptors and steroid biosynthesis genes in ovarian tissues. Patuletin demonstrated a promising protective approach against the biological model of PCOS by increasing the inflammation in ovarian tissues with consequent regulation of growth factors, enzymes, and hormones, and might be used as adjuvant therapy in the treatment of problems related to female reproductive health.
- 18 May 2024
- Published by Springer Nature in Journal of Cluster Science
- Vol. 35 (6) , 2007-2017
Lecithin Derived Nano-Propyl Gallate as Non-Toxic Anti-Inflammatory Agent: Synthesis, In-Vitro and In-Vivo Investigations
- 18 May 2024
- Published by Springer Nature in Journal of Cluster Science
- Vol. 35 (6) , 2007-2017
Lecithin Derived Nano-Propyl Gallate as Non-Toxic Anti-Inflammatory Agent: Synthesis, In-Vitro and In-Vivo Investigations
- 16 November 2023
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (6) , 3303-3316
A new acyl derivative of sulfadimethoxine inhibits phagocyte oxidative burst and ameliorates inflammation in a mice model of zymosan-induced generalised inflammation
Chronic inflammation and oxidative stress play a pivotal role in the pathophysiology of most challenging illnesses, including cancer, Alzheimer’s, cardiovascular and autoimmune diseases. The present study aimed to investigate the anti-inflammatory potential of a new sulfadimethoxine derivative N-(4-(N-(2,6-dimethoxypyrimidin-4-yl) sulfamoyl) phenyl) dodecanamide (MHH-II-32). The compound was characterised by applying 1H-, 13C-NMR, EI–MS and HRFAB–MS spectroscopic techniques. The compound inhibited zymosan-induced oxidative bursts from whole blood phagocytes and isolated polymorphonuclear cells with an IC50 value of (2.5 ± 0.4 and 3.4 ± 0.3 µg/mL), respectively. Furthermore, the inhibition of nitric oxide with an IC50 (3.6 ± 2.2 µg/mL) from lipopolysaccharide-induced J774.2 macrophages indicates its in vitro anti-inflammatory efficacy. The compound did not show toxicity towards normal fibroblast cells. The observational findings, gross anatomical analysis of visceral organs and serological tests revealed the non-toxicity of the compound at the highest tested intraperitoneal (IP) dose of 100 mg/kg in acute toxicological studies in Balb/c mice. The compound treatment (100 mg/kg) (SC) significantly (P < 0.001) downregulated the mRNA expression of inflammatory markers TNF-α, IL-1β, IL-2, IL-13, and NF-κB, which were elevated in zymosan-induced generalised inflammation (IP) in Balb/c mice while upregulated the expression of anti-inflammatory cytokine IL-10, which was reduced in zymosan-treated mice. No suppressive effect was observed at the dose of 25 mg/kg. Ibuprofen was taken as a standard drug. The results revealed that the new acyl derivative of sulfadimethoxine has an immunomodulatory effect against generalised inflammatory response with non-toxicity both in vitro and in vivo, and has therapeutic potential for various chronic inflammatory illnesses.
- 16 November 2023
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (6) , 3303-3316
A new acyl derivative of sulfadimethoxine inhibits phagocyte oxidative burst and ameliorates inflammation in a mice model of zymosan-induced generalised inflammation
Chronic inflammation and oxidative stress play a pivotal role in the pathophysiology of most challenging illnesses, including cancer, Alzheimer’s, cardiovascular and autoimmune diseases. The present study aimed to investigate the anti-inflammatory potential of a new sulfadimethoxine derivative N-(4-(N-(2,6-dimethoxypyrimidin-4-yl) sulfamoyl) phenyl) dodecanamide (MHH-II-32). The compound was characterised by applying 1H-, 13C-NMR, EI–MS and HRFAB–MS spectroscopic techniques. The compound inhibited zymosan-induced oxidative bursts from whole blood phagocytes and isolated polymorphonuclear cells with an IC50 value of (2.5 ± 0.4 and 3.4 ± 0.3 µg/mL), respectively. Furthermore, the inhibition of nitric oxide with an IC50 (3.6 ± 2.2 µg/mL) from lipopolysaccharide-induced J774.2 macrophages indicates its in vitro anti-inflammatory efficacy. The compound did not show toxicity towards normal fibroblast cells. The observational findings, gross anatomical analysis of visceral organs and serological tests revealed the non-toxicity of the compound at the highest tested intraperitoneal (IP) dose of 100 mg/kg in acute toxicological studies in Balb/c mice. The compound treatment (100 mg/kg) (SC) significantly (P < 0.001) downregulated the mRNA expression of inflammatory markers TNF-α, IL-1β, IL-2, IL-13, and NF-κB, which were elevated in zymosan-induced generalised inflammation (IP) in Balb/c mice while upregulated the expression of anti-inflammatory cytokine IL-10, which was reduced in zymosan-treated mice. No suppressive effect was observed at the dose of 25 mg/kg. Ibuprofen was taken as a standard drug. The results revealed that the new acyl derivative of sulfadimethoxine has an immunomodulatory effect against generalised inflammatory response with non-toxicity both in vitro and in vivo, and has therapeutic potential for various chronic inflammatory illnesses.
- 10 August 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110741
N-(2-hydroxy phenyl) acetamide ameliorate inflammation and doxorubicin-induced nephrotoxicity in rats
- 10 August 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110741
N-(2-hydroxy phenyl) acetamide ameliorate inflammation and doxorubicin-induced nephrotoxicity in rats
- Open Access
- 18 January 2023
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 23 (1) , 1-13
Honey proteins regulate oxidative stress, inflammation and ameliorates hyperglycemia in streptozotocin induced diabetic rats
Background: Diabetes Mellitus (DM) poses a serious health problem worldwide and several inflammatory mediators are involved in the pathogenesis of this disease. Honey composed of various constituents which have been proven to have immunomodulatory and anti-inflammatory properties. The aim of this study is to investigate the in vitro and in vivo effects of Ziziphus honey and its isolated crude proteins in modulation of immune system and inflammation involved in the pathogenesis of diabetes. Methodology: The proteins from Ziziphus honey were isolated by ammonium sulfate precipitation and estimated by Bradford method. In vitro anti-inflammatory activities were evaluated by inhibition of reactive oxygen species (ROS) from phagocytes via chemiluminescence immunoassay and nitric oxide (NO) by Griess method. Cytotoxicity was evaluated by MTT Assay. The comparative effect of oral and IP routes of honey and isolated proteins was observed in streptozotocin (STZ) induced diabetic male Wistar rats. qRT-PCR technique was utilized for gene expression studies. Results: The honey proteins suppressed phagocyte oxidative burst and nitric oxide (NO) at significantly lower concentrations as compared to crude honey. The isolated proteins showed promising anti-inflammatory and hypoglycemic effects along with maintenance of body weight of rodents via both oral and IP routes, with significant down-regulation of inflammatory markers TNF-α, IL-1β, IFN-γ, iNOS, caspase 1, Calgranulin A (S100A8) and NF-κB expression in diabetic rats. Conclusion: The isolated honey proteins showed better immunomodulatory and therapeutic potential at significantly lower doses as compared to crude honey.
- 18 January 2023
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 23 (1) , 1-13
Open AccessHoney proteins regulate oxidative stress, inflammation and ameliorates hyperglycemia in streptozotocin induced diabetic rats
Background: Diabetes Mellitus (DM) poses a serious health problem worldwide and several inflammatory mediators are involved in the pathogenesis of this disease. Honey composed of various constituents which have been proven to have immunomodulatory and anti-inflammatory properties. The aim of this study is to investigate the in vitro and in vivo effects of Ziziphus honey and its isolated crude proteins in modulation of immune system and inflammation involved in the pathogenesis of diabetes. Methodology: The proteins from Ziziphus honey were isolated by ammonium sulfate precipitation and estimated by Bradford method. In vitro anti-inflammatory activities were evaluated by inhibition of reactive oxygen species (ROS) from phagocytes via chemiluminescence immunoassay and nitric oxide (NO) by Griess method. Cytotoxicity was evaluated by MTT Assay. The comparative effect of oral and IP routes of honey and isolated proteins was observed in streptozotocin (STZ) induced diabetic male Wistar rats. qRT-PCR technique was utilized for gene expression studies. Results: The honey proteins suppressed phagocyte oxidative burst and nitric oxide (NO) at significantly lower concentrations as compared to crude honey. The isolated proteins showed promising anti-inflammatory and hypoglycemic effects along with maintenance of body weight of rodents via both oral and IP routes, with significant down-regulation of inflammatory markers TNF-α, IL-1β, IFN-γ, iNOS, caspase 1, Calgranulin A (S100A8) and NF-κB expression in diabetic rats. Conclusion: The isolated honey proteins showed better immunomodulatory and therapeutic potential at significantly lower doses as compared to crude honey.
- 11 August 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (3) , 555-570
In-vitro inhibition of NLRP3 inflammasome by 3,6-dihydroxyflavone (3,6-DHF): a therapeutic strategy for the treatment of chronic inflammatory and autoimmune diseases
Nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex has an important role in immune system and its abnormal activation is associated with the pathogenesis of various inflammatory and auto-immune diseases. The study reveals the anti-inflammatory effects of 3,6-dihydroxyflavone (3,6-DHF). Here, we aimed to determine the inhibitory effects of 3,6-DHF on NLRP3 inflammasome and its associated components, thereby determining the signaling pathways involved in the inhibition. Reactive oxygen species (ROS) and nitric oxide (NO) were quantified by chemiluminescence and Griess methods, respectively. Inflammatory cell model was induced in human leukemic monocytes (THP-1). mRNA levels were estimated through real-time RT-PCR, protein expressions were evaluated by protein slot blot and immunocytochemistry, MTT and alamar blue assays were employed for toxicity studies. The compound 3,6-DHF was found to be the potent inhibitor of NLRP3 inflammasome by targeting the molecules involve in its activation pathway. Anti-inflammatory effects were revealed by inhibition of ROS and NO, reduction in the transcription of caspase-1, ASC, IL-1β and TLR-4 was observed along with the marked inhibition of NLRP3, IL-18, NF-κB and pNF-κB at translational level. 3,6-DHF was non-toxic on normal human fibroblast (BJ) and THP-1 cells and, could be a potential therapeutic agent in NLRP3 inflammasome driven diseases.
- 11 August 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (3) , 555-570
In-vitro inhibition of NLRP3 inflammasome by 3,6-dihydroxyflavone (3,6-DHF): a therapeutic strategy for the treatment of chronic inflammatory and autoimmune diseases
Nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex has an important role in immune system and its abnormal activation is associated with the pathogenesis of various inflammatory and auto-immune diseases. The study reveals the anti-inflammatory effects of 3,6-dihydroxyflavone (3,6-DHF). Here, we aimed to determine the inhibitory effects of 3,6-DHF on NLRP3 inflammasome and its associated components, thereby determining the signaling pathways involved in the inhibition. Reactive oxygen species (ROS) and nitric oxide (NO) were quantified by chemiluminescence and Griess methods, respectively. Inflammatory cell model was induced in human leukemic monocytes (THP-1). mRNA levels were estimated through real-time RT-PCR, protein expressions were evaluated by protein slot blot and immunocytochemistry, MTT and alamar blue assays were employed for toxicity studies. The compound 3,6-DHF was found to be the potent inhibitor of NLRP3 inflammasome by targeting the molecules involve in its activation pathway. Anti-inflammatory effects were revealed by inhibition of ROS and NO, reduction in the transcription of caspase-1, ASC, IL-1β and TLR-4 was observed along with the marked inhibition of NLRP3, IL-18, NF-κB and pNF-κB at translational level. 3,6-DHF was non-toxic on normal human fibroblast (BJ) and THP-1 cells and, could be a potential therapeutic agent in NLRP3 inflammasome driven diseases.
- 9 July 2022
- Published by Springer Nature in Journal of Cluster Science
- Vol. 34 (3) , 1369-1379
Synthesis and Characterization of Novel Lecithin Derived Nano-Formulation of Octyl and Dodecyl Gallate for Targeting B Cell Associated Non-Hodgkin’s Lymphoma
- 9 July 2022
- Published by Springer Nature in Journal of Cluster Science
- Vol. 34 (3) , 1369-1379
Synthesis and Characterization of Novel Lecithin Derived Nano-Formulation of Octyl and Dodecyl Gallate for Targeting B Cell Associated Non-Hodgkin’s Lymphoma